Hamlet BioPharma Juggles Bladder Cancer and Tuberculosis Programs Ahead of May 22 Report
Published on 05/17/2026 at 18:06 | Redaktion boerse-global.de
The stock of Swedish biotech Hamlet BioPharma has already surged roughly 55% over the past year, but the real test comes on May 22 when the company releases its fiscal third-quarter results. Investors are looking beyond the headline numbers, eager for concrete updates on two distinct pipelines: the lead bladder cancer candidate Alpha1H and a lesser-known tuberculosis program that could add a second growth engine.
Diversifying Beyond Oncology
Hamlet’s partnership with South Korean biotech ImmunoForge marks an unexpected but strategic expansion into infectious disease. The duo is co-developing a slow-release formulation for the peptide drug NZX, which targets lung tuberculosis. In animal models, the compound has demonstrated activity against antibiotic-resistant bacterial strains, a growing global health threat. Under the agreement, both companies will share intellectual property and development costs, preserving Hamlet’s cash reserves while accessing external expertise.
Alpha1H Commercialization Heats Up
Meanwhile, the core oncology asset Alpha1H is advancing on multiple fronts. Hamlet has signed a non-binding letter of intent with a northern German uro-oncology specialist to negotiate exclusive global marketing rights. The deal remains subject to legal and financial due diligence, with advisory firm PharmaVentures guiding the discussions. The market opportunity is substantial: bladder cancer treatment alone costs Europe more than €4.9 billion annually, and recurrence rates after initial surgery reach up to 80%.
Should investors sell immediately? Or is it worth buying Hamlet Pharma AB?
The scientific foundation for those talks rests on a successful Phase II trial, where the high-dose group saw an average tumor shrinkage of 59%, an 80% response rate, and no severe adverse events. Alpha1H attacks cancer cells locally within the bladder, limiting systemic toxicity.
FDA Lays Out Phase III Roadmap
Regulatory momentum is also building. The U.S. Food and Drug Administration has approved the Phase III study design for Alpha1H, setting primary endpoints of complete response rate and event-free survival. The drug already holds Fast Track status, which accelerates the approval timeline. Patient enrollment will begin as soon as ethics committees give the go-ahead.
On the technical side, the stock has pulled back through a short-term support line, with chartists now eyeing the next floor at 6.00 Swedish kronor and resistance at 8.80 kronor.
What Investors Expect on May 22
The third-quarter report will need to deliver more than just financial figures. The market will scrutinize the cash burn rate to gauge how long current reserves can fund the upcoming Phase III study. Equally important are updates on the German partner negotiations and a firm timeline for launching the pivotal trial. Any definitive agreement on Alpha1H would likely trigger a re-rating.
Ad
Hamlet Pharma AB Stock: New Analysis - 17 May
Fresh Hamlet Pharma AB information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
